← All trials
NCT04514237
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2019
- Primary completion
- Jan 22, 2020
- Completion date
- Jan 22, 2020
- First posted
- Aug 14, 2020
- Last posted
- Nov 18, 2020
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Boston PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.